Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Expedeon AG, DE000A2YN801

Expedeon AG, DE000A2YN801

02.01.2020 - 07:32:29

Expedeon AG: Expedeon AG and Abcam plc close EUR 120 million transaction

Investor website: www.investors.expedeon.com

MC Services AG (Investor Relations and International Media Relations)

Raimund Gabriel Managing Partner Phone: +49 89 210228 0 Email: expedeon@mc-services.eu

About Expedeon AG: www.expedeon.com

Expedeon is an enabler of exciting advances in medical science and patient care. The Company's core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. After selling the proteomics and immunology business, Expedeon AG will focus on manufacturing highly pure DNA for use in gene therapies and gene vaccines. Expedeon AG has offices in Germany, Spain, UK, and the US. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXNN; ISIN: DE000A2YN801).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expedeon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expedeon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###

Additional features:Document: http://n.eqs.com/c/fncls.ssp?u=CXBIEFSVAJDocument title: Abcam_Eng

02.01.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: Expedeon AG Waldhofer Str. 102 69123 Heidelberg

Germany Phone: +49 (0) 6221 3540 125 Fax: +49 (0) 6221 3540 127 E-mail: investors@expedeon.com Internet: www.expedeon.com ISIN: DE000A2YN801 WKN: A2YN80 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 945259   End of News DGAP News Service

945259  02.01.2020 

@ dgap.de